骨质疏松初级预防中骨合成代谢治疗后抗骨吸收序贯治疗的及时性:美国队列研究
该回顾性队列研究利用美国商业、Medicare Advantage和传统Medicare索赔数据,纳入2011至2022年间起始romosozumab、特立帕肽或阿巴洛肽的≥50岁成人,评估初级骨折预防中骨合成代谢治疗后及时序贯抗骨吸收治疗的模式与预测因素。结果显示仅25%患者及时序贯,12%完成全程治疗且及时序贯,内分泌或风湿科随访及较晚起始年份与更髙及时序贯几率相关。
要点
- 仅25%患者在骨合成代谢治疗后3个月内启动抗骨吸收治疗,40%未序贯。
- 仅12%患者完成全程骨合成代谢治疗并实现及时序贯。
- 内分泌科或风湿科随访相比初级保健提高及时序贯几率。
核心结论
- 仅四分之一患者在骨合成代谢治疗后接受及时序贯治疗,八分之一完成全程序列。
- 需要改进初级骨折预防中的序贯治疗策略。
研究设计与样本
- 回顾性队列研究,使用美国商业、Medicare Advantage和传统Medicare索赔数据。
主要发现
- 30%完成骨合成代谢治疗(romosozumab中位12.9个月;特立帕肽/阿巴洛肽中位23.4个月)。
- 25%及时序贯,24%延迟序贯,12%重新起始骨合成代谢,40%未序贯。
- 内分泌科随访相比初级保健的OR为1.31(95%CI 1.17-1.48),风湿科为1.45(1.30-1.62)。
- 50-64岁相比65-74岁的OR为0.67(0.58-0.77),Medicare Advantage相比传统Medicare的OR为0.85(0.74-0.98),近期住院OR为0.88(0.80-0.97)。
- 2021年起始相比2011年起始的OR为4.27(3.63-5.05)。
关键数值与推荐
- 及时序贯定义为骨合成代谢治疗完成后3个月内启动抗骨吸收药物。
- 全程骨合成代谢治疗定义为romosozumab≥12个月,特立帕肽或阿巴洛肽≥18个月。
临床怎么用
- 对接受骨合成代谢治疗的患者应主动规划并及时启动抗骨吸收序贯治疗。
- 内分泌科或风湿科参与管理可能提高及时序贯率。
- 年轻患者(50-64岁)、Medicare Advantage参保者及近期住院者需关注序贯治疗风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Osteoanabolic therapy for osteoporosis should be followed by antiresorptive treatment ("consolidation") to preserve bone mass. Although osteoanabolic therapy is increasingly endorsed for primary fracture prevention, real-world implementation of consolidation remains unknown. OBJECTIVE: To assess patterns and predictors of timely consolidation after osteoanabolic therapy for primary fracture prevention. METHODS: We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initiation of an antiresorptive medication within 3 months after osteoanabolic therapy. Secondary outcomes included delayed consolidation (initiation >3 months after completion), osteoanabolic restart following a treatment gap, and no consolidation therapy. We further distinguished participants who completed the full osteoanabolic course, defined as ≥12 months for romosozumab and ≥18 months for teriparatide or abaloparatide. Multivariable logistic regression models were used to identify predictors of consolidation patterns. RESULTS: Among 15 389 patients (mean age 70.6 years; 89% women; 85% White), 30% completed osteoanabolic therapy (median, 12.9 months for romosozumab; 23.4 months for teriparatide/abaloparatide). Overall, 25% had timely consolidation, 24% delayed consolidation, 12% restarted osteoanabolics, and 40% had no consolidation; only 12% completed therapy with timely consolidation. Timely consolidation was more likely with endocrinology (OR 1.31; 95% CI, 1.17-1.48) or rheumatology (OR 1.45; 1.30-1.62) vs primary care, and less likely among patients aged 50-64 years (OR 0.67; 0.58-0.77) vs 65-74, those enrolled in Medicare Advantage (OR 0.85; 0.74-0.98) vs traditional Medicare, or those recently hospitalized (OR 0.88; 0.80-0.97). Odds increased over time (OR 4.27; 3.63-5.05 for 2021 vs 2011 starts). CONCLUSION: Only 1 in 4 patients received timely consolidation therapy after osteoanabolic treatment, and 1 in 8 completed the full sequence. Strategies to improve consolidation in primary fracture prevention are needed.
引用
- Badour S, McCoy RG, Takagi M, et al. Timeliness of antiresorptive consolidation after anabolic therapy for primary fracture prevention: A US cohort study. J Clin Endocrinol Metab. 2026. PMID: 41778369. doi:10.1210/clinem/dgag092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。